Global pharma powerhouse Novo Nordisk is heading into the 2026 Scientific Sessions of the American Diabetes Association (ADA) in New Orleans with a sweeping showcase of its cardiometabolic pipeline.

 

The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs.

 

The company said Phase 3 REIMAGINE 1–3 results will highlight the investigational therapy CagriSema, examining its impact on glycemic control and weight loss across multiple type 2 diabetes treatment backgrounds. 

 

In total, 40 abstracts will be presented, spanning early- and late-stage programs and reinforcing what the company calls a rapidly expanding evidence base for its GLP-1–centered approach.

 

“The ADA’s 2026 Scientific Sessions underscores the breadth and strength of our approach to cardiometabolic diseases. From amylin-based pipeline candidates to continued expansion of our portfolio, we are building on the established and unique profile of semaglutide,” said Martin Holst Lange, executive vice president of Research & Development and chief scientific officer at Novo Nordisk. 

 

“As pioneers in this space, we remain focused on advancing innovation that can meaningfully improve the lives of millions living with serious chronic diseases.”

 

Alongside CagriSema, Novo Nordisk will present Phase 2 data on once-weekly injectable zenagamtide and new findings across established products Ozempic and Wegovy, both based on semaglutide, extending evidence across cardiometabolic indications.

 

A wide slate of analyses will probe semaglutide’s effects beyond glucose and weight, including cardiovascular risk markers, biological aging, kidney function, asthma outcomes, and sleep apnea in patients with obesity and cardiovascular disease.

 

Pipeline assets beyond semaglutide will also take center stage, including insulin Icodec, combination therapy IcoSema, and the investigational liver disease drug efruxifermin, underscoring the company’s push into multi-organ metabolic disease.

 

The company emphasized that investigational therapies including CagriSema, zenagamtide, IcoSema, and efruxifermin are not approved in the United States, and their safety and efficacy have not yet been established.

 

With dozens of presentations spanning metabolic, cardiovascular, kidney, and liver outcomes, Novo Nordisk is positioning its ADA presence as a broad, data-heavy signal of its ambition to dominate the next phase of cardiometabolic drug development.